• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Dyne Therapeutics, Inc. - Common Stock (NQ:DYN)

16.13 -0.14 (-0.86%)
Delayed Quote Updated: 3:36 PM EDT, Oct 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,208,073
Open 16.33
Bid (Size) 16.12 (300)
Ask (Size) 16.14 (300)
Prev. Close 16.27
Today's Range 15.91 - 16.73
52wk Range 14.00 - 27.30
Shares Outstanding 58,310,703
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
September 29, 2026
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 17, 2026
From Dyne Therapeutics, Inc.
Via GlobeNewswire

Performance

52-Week Range 40.9% below 52-week high
16.13
14.0052W Low 27.3052W High
1 Week 2.6% below 1-week high
14.131W Low 16.561W High

Dyne Therapeutics, Inc. - Common Stock (DYN) traded between $14.00 and $27.30 over the past 52 weeks and last traded at $16.13, 40.9% below its 52-week high. Over the past week it ranged between $14.13 and $16.56.

Past 12 Months
+7.2%
-5.8%
-32.3%
-16.0%
-12.8%
-5.6%
1W +$1.09
1M -$0.99
3M -$7.70
6M -$3.08
YTD -$2.37
1Y -$0.95

DYN was -5.6% over the past year, -16.0% over six months, -12.8% year to date, +7.2% in the last week.

12 Months vs Market
DYN
-5.6%
DIA
+12.8%
SPY
+15.2%
QQQ
+18.7%
IWM
+11.4%

Over the past 12 months DYN returned -5.6% versus DIA (Dow) +12.8%, SPY (S&P 500) +15.2%, QQQ (Nasdaq 100) +18.7% and IWM (Russell 2000) +11.4%.

Volume & Liquidity 0.41× 3-mo avg
Today 1,208,073 3-mo avg 3.0M
1W
2.8M
1M
3.2M
3M
3.0M
6M
2.4M
YTD
2.3M
1Y
2.5M

DYN most recently traded 1,208,073 shares against a 3-month average daily volume of 3.0M.

More News

Read More
There are notable gap-ups and gap-downs in today's session. ↗
September 08, 2026
Via Chartmill
These stocks are moving in today's pre-market session ↗
September 08, 2026
Via Chartmill
News headline image
Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) at Upcoming Medical Meetings
September 08, 2026
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics to Present Preclinical Data for Multiple Development Candidates for Duchenne Muscular Dystrophy (DMD) at 27th Annual NMSG Scientific Meeting
September 03, 2026
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics to Participate in Upcoming Investor Conferences
September 02, 2026
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 20, 2026
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
July 29, 2026
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)
July 28, 2026
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 24, 2026
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
July 23, 2026
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock
July 21, 2026
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
July 21, 2026
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)
July 20, 2026
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026? ↗
July 04, 2026
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Dyne Therapeutics vs. Vertex Pharmaceuticals: Which Drug Innovator Stock Is a Better Buy in 2026? ↗
July 01, 2026
Via The Motley Fool
News headline image
Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
June 26, 2026
Via The Motley Fool
News headline image
Dyne Therapeutics Appoints Barry Greene to Board of Directors
June 22, 2026
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 18, 2026
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc.
June 17, 2026
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1)
June 03, 2026
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge ↗
May 30, 2026
Via The Motley Fool
News headline image
Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean ↗
May 30, 2026
Via The Motley Fool
News headline image
Dyne Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)
May 26, 2026
From Dyne Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Dyne Therapeutics, Inc. - Common Stock publicly traded?
Yes, Dyne Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Dyne Therapeutics, Inc. - Common Stock trade on?
Dyne Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Dyne Therapeutics, Inc. - Common Stock?
The ticker symbol for Dyne Therapeutics, Inc. - Common Stock is DYN on the Nasdaq Stock Market
What is the current price of Dyne Therapeutics, Inc. - Common Stock?
The current price of Dyne Therapeutics, Inc. - Common Stock is 16.13
When was Dyne Therapeutics, Inc. - Common Stock last traded?
The last trade of Dyne Therapeutics, Inc. - Common Stock was at 10/21/26 03:36 PM ET
What is the market capitalization of Dyne Therapeutics, Inc. - Common Stock?
The market capitalization of Dyne Therapeutics, Inc. - Common Stock is 940.55M
How many shares of Dyne Therapeutics, Inc. - Common Stock are outstanding?
Dyne Therapeutics, Inc. - Common Stock has 941M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap